← Atlas Theme · spans 1 topics
Rare disease pipelines must target unified disease mechanisms rather than specific genetic mutations.
To capture commercially viable patient volumes, drug developers are bypassing narrow, mutation-specific targets in favor of broad, mutation-agnostic therapies that address shared biological pathways.
1
Topics it spans
2
Findings citing it
—
Evidence window
The convergence
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
Science & Health
FDA Approves Regeneron's Pasatru, First Treatment to Reduce FOP Flare-Ups and Lesions Pasatru achieves clinical efficacy in a rare disease by targeting the unified, overarching Activin A protein pathway rather than correcting individual downstream mutations.
Science & Health
FDA Accepts Nanoscope's BLA for Optogenetic Gene Therapy MCO-010 in Retinitis Pigmentosa Nanoscope's gene therapy targets retinitis pigmentosa via a mutation-agnostic pathway, bypassing the commercial limits of mutation-specific treatments to restore vision across the entire disease population.